Agile Therapeutics (AGRX)
NASDAQ:AGRX

Agile Therapeutics Stock Price & Analysis

1,454 Followers

AGRX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.18 - $29.56
Previous Close$0.2
Volume441.97K
Average Volume (3M)1.07M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)>-0.1
Beta1.01
Next EarningsMar 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-14.94
Shares Outstanding40,614,527
R-Squared0.04
Standard Deviation0.33
10 Day Avg. Volume540,578
30 Day Avg. Volume1,074,159
Price to Book (P/B)1.30
Price to Sales (P/S)1.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Alpha-0.05
Number of Analyst Covering1


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

AGRX FAQ

What was Agile Therapeutics’s price range in the past 12 months?
Agile Therapeutics lowest stock price was $0.18 and its highest was $29.56 in the past 12 months.
    What is Agile Therapeutics’s market cap?
    Currently, no data Available
    When is Agile Therapeutics’s upcoming earnings report date?
    Agile Therapeutics’s upcoming earnings report date is Mar 14, 2023 which is in 102 days.
      How were Agile Therapeutics’s earnings last quarter?
      Agile Therapeutics released its earnings results on Nov 07, 2022. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.44 by -$0.09.
        Is Agile Therapeutics overvalued?
        According to Wall Street analysts Agile Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Agile Therapeutics pay dividends?
          Agile Therapeutics does not currently pay dividends.
          What is Agile Therapeutics’s EPS estimate?
          Agile Therapeutics’s EPS estimate is -$0.23.
            How many shares outstanding does Agile Therapeutics have?
            Agile Therapeutics has 40,614,530 shares outstanding.
              What happened to Agile Therapeutics’s price movement after its last earnings report?
              Agile Therapeutics reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.44. Following the earnings report the stock price went down -18.75%.
                Which hedge fund is a major shareholder of Agile Therapeutics?
                Among the largest hedge funds holding Agile Therapeutics’s share is Perceptive Advisors LLC. It holds Agile Therapeutics’s shares valued at 158K.

                  ---

                  Agile Therapeutics Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -99.21%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -791.16%
                  Trailing 12-Months
                  Asset Growth
                  -49.67%
                  Trailing 12-Months
                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Agile Therapeutics

                  Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Virpax Pharmaceuticals
                  Petros Pharmaceuticals
                  Kala Pharmaceuticals
                  GB Sciences
                  Landos Biopharma

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis